Li-Bing Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Li-Bing Guo has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Huan-Xin Lin
State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
1 shared publication - Hui Lin
State Key Laboratory of Oncology in South China, Sun Yat -sen University Cancer center, Guangzhou, Guangdong 510060, People's Republic of China
1 shared publication - Nan Ge
Surgical Intensive Care Unit, Xiangtan Central Hospital, Hunan Province, Xiangtan, 411100, China
1 shared publication - Qiuli Li
Department of Head and Neck Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou China
1 shared publication - Rui Sun
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China
1 shared publication Shengsong Yin
Department of Oncology, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong 510317, P.R. China
1 shared publication
Latest Publications
- Open Access
- 13 May 2019
- Published by Spandidos Publications in Oncology Letters
- Vol. 18 (1) , 764-770
Expression and clinical significance of miRNA-145 and miRNA-218 in laryngeal cancer
Expression of miRNA-145 and miRNA-218 in serum of patients with laryngeal cancer and the relationship between them and the clinicopathological parameters and prognosis were investigated. The clinical medical records of 132 patients with laryngeal cancer, who were admitted to Guangdong Second Provincial General Hospital from February 2009 to March 2014, were retrospectively analyzed and comprised the study group. The data of physical examinations of 56 healthy volunteers who took physical examinations in the same hospital comprised the control group. RT-qPCR was used to detect the expression levels of miRNA-145 and miRNA-218 in serum of the patients in the two groups. According to the relative expression levels of miRNA-145 and miRNA-218 in serum of the patients in the study group on the day when they left hospital, the study group was divided into the high expression group (n=73 patients) and the low expression group (n=59 patients). The patients received a 48-month follow-up visit and their survival condition was recorded and the Kaplan-Meier was used to carry out the survival analysis. The expression levels of miRNA-145 and miRNA-218 in serum of the patients in the study group were lower than those in the control group (P<0.05). The median survival time of the patients in the high expression group was 30 months while the median survival time of the patients in the low expression group was 26 months. The expression levels of miRNA-145 and miRNA‑218 in serum of patients with laryngeal cancer decreased, the higher the expression levels of miRNA‑145 and miRNA-218 in serum of patients with laryngeal cancer were, the better the prognosis was. miRNA-145 and miRNA‑218 were used as indicators of assessing the prognosis of patients with laryngeal cancer.
- 13 May 2019
- Published by Spandidos Publications in Oncology Letters
- Vol. 18 (1) , 764-770
Open AccessExpression and clinical significance of miRNA-145 and miRNA-218 in laryngeal cancer
Expression of miRNA-145 and miRNA-218 in serum of patients with laryngeal cancer and the relationship between them and the clinicopathological parameters and prognosis were investigated. The clinical medical records of 132 patients with laryngeal cancer, who were admitted to Guangdong Second Provincial General Hospital from February 2009 to March 2014, were retrospectively analyzed and comprised the study group. The data of physical examinations of 56 healthy volunteers who took physical examinations in the same hospital comprised the control group. RT-qPCR was used to detect the expression levels of miRNA-145 and miRNA-218 in serum of the patients in the two groups. According to the relative expression levels of miRNA-145 and miRNA-218 in serum of the patients in the study group on the day when they left hospital, the study group was divided into the high expression group (n=73 patients) and the low expression group (n=59 patients). The patients received a 48-month follow-up visit and their survival condition was recorded and the Kaplan-Meier was used to carry out the survival analysis. The expression levels of miRNA-145 and miRNA-218 in serum of the patients in the study group were lower than those in the control group (P<0.05). The median survival time of the patients in the high expression group was 30 months while the median survival time of the patients in the low expression group was 26 months. The expression levels of miRNA-145 and miRNA‑218 in serum of patients with laryngeal cancer decreased, the higher the expression levels of miRNA‑145 and miRNA-218 in serum of patients with laryngeal cancer were, the better the prognosis was. miRNA-145 and miRNA‑218 were used as indicators of assessing the prognosis of patients with laryngeal cancer.
- Open Access
- 30 March 2012
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 10 (1) , 64
Expression TGM2 and BNIP3 have prognostic significance in laryngeal cancer patients receiving surgery and postoperative radiotherapy: A retrospective study
Background: This study was designed to determine the pattern and correlation between expression of the HIF-1α transcriptional targets TGM2 and BNIP3 in laryngeal cancer, and investigate the association of BNIP3 and TGM2 with clinical outcome in laryngeal squamous cell carcinoma (SCC) patients receiving postoperative radiotherapy. Methods: Immunostaining with antibodies specific to BNIP3 and TGM2 was performed in formalin-fixed, paraffin-embedded specimens from 148 laryngeal SCC patients. BNIP3 and TGM2 expression was scored as high or low, based on the number of tumor cells stained and the staining intensity. All patients received postoperative radiotherapy. Patient follow up and clinicopathological data were compared using the Chi-squared test, univariate and multivariate analyses, and survival curves were generated using the Kaplan-Meier method and log-rank test. Results: The 3, 5 and 10-year overall survival rates (OS) for all patients were 77.7%, 71.6%, 56.4%, respectively. Primary tumor site, T stage, overall stage, lymph-node metastasis, BNIP3 expression and TGM2 expression were significant prognostic factors for OS in univariate analysis. Negative cervical lymph nodes, high BNIP3 expression and low TGM2 expression were independent prognostic factors of improved OS in multivariate analysis. BNIP3 expression correlates with TGM2 expression in laryngeal SCC (P = 0.012). Conclusions: This study indicates that lymph-node metastasis, BNIP3 expression and TGM2 expression are independent prognostic factors in laryngeal SCC patients receiving postoperative radiotherapy. Further studies are required to investigate how BNIP3 and/or TGM2 influence the prognosis of laryngeal SCC patients treated with postoperative radiotherapy, and to determine how TGM2 and BNIP3 expression are regulated.
- 30 March 2012
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 10 (1) , 64
Open AccessExpression TGM2 and BNIP3 have prognostic significance in laryngeal cancer patients receiving surgery and postoperative radiotherapy: A retrospective study
Background: This study was designed to determine the pattern and correlation between expression of the HIF-1α transcriptional targets TGM2 and BNIP3 in laryngeal cancer, and investigate the association of BNIP3 and TGM2 with clinical outcome in laryngeal squamous cell carcinoma (SCC) patients receiving postoperative radiotherapy. Methods: Immunostaining with antibodies specific to BNIP3 and TGM2 was performed in formalin-fixed, paraffin-embedded specimens from 148 laryngeal SCC patients. BNIP3 and TGM2 expression was scored as high or low, based on the number of tumor cells stained and the staining intensity. All patients received postoperative radiotherapy. Patient follow up and clinicopathological data were compared using the Chi-squared test, univariate and multivariate analyses, and survival curves were generated using the Kaplan-Meier method and log-rank test. Results: The 3, 5 and 10-year overall survival rates (OS) for all patients were 77.7%, 71.6%, 56.4%, respectively. Primary tumor site, T stage, overall stage, lymph-node metastasis, BNIP3 expression and TGM2 expression were significant prognostic factors for OS in univariate analysis. Negative cervical lymph nodes, high BNIP3 expression and low TGM2 expression were independent prognostic factors of improved OS in multivariate analysis. BNIP3 expression correlates with TGM2 expression in laryngeal SCC (P = 0.012). Conclusions: This study indicates that lymph-node metastasis, BNIP3 expression and TGM2 expression are independent prognostic factors in laryngeal SCC patients receiving postoperative radiotherapy. Further studies are required to investigate how BNIP3 and/or TGM2 influence the prognosis of laryngeal SCC patients treated with postoperative radiotherapy, and to determine how TGM2 and BNIP3 expression are regulated.